Re: Metformin harmful for the heart ??

[Guest guest]

--- In , " rizwankherati " <helper11@e...>

wrote:

> Hi,

>

> I am a non diabetic man with some insulin resistance and FBS leves of

> 100+, I was considering the use of Metformin for its potential life

> extension benefits. However, the following study appears to be

> troubling. I request comments and opinions and any other relevent

studies/facts.

>

> Best regards

>

> Rizwan Kherati

>

Rizwan,

Metformin may cause lactic acidosis which can be fatal. The sudden

development of a slow or irregular heartbeat may be a sign of lactic

acidosis.

http://www.drugs.com/metformin.html

Check with your doctor, but before taking any drugs, you may want to

try cutting down your calories, specially carbohydrates, and adding a

teaspoon of cinnamon to your daily diet. Check out the following sources.

Tony

================

How I Defeated Type II Diabetes

http://shurie.com/lee/writing_defeat_diabetes.htm

===

Diabetes Res Clin Pract. 2003 Dec;62(3):139-48.

Cinnamon extract (traditional herb) potentiates in vivo

insulin-regulated glucose utilization via enhancing insulin signaling

in rats.

Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y.

Department of Sports Medicine, Graduate School of Medicine, Nagoya

University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan.

Cinnamon has been shown to potentiate the insulin effect through

upregulation of the glucose uptake in cultured adipocytes. In the

present study, we evaluated the effect of the cinnamon extract on the

insulin action in awaked rats by the euglycemic clamp and further

analyzed possible changes in insulin signaling occurred in skeletal

muscle. The rats were divided into saline and cinnamon extract (30 and

300 mg/kg BW-doses: C30 and C300) oral administration groups. After

3-weeks, cinnamon extract treated rats showed a significantly higher

glucose infusion rate (GIR) at 3 mU/kg per min insulin infusions

compared with controls (118 and 146% of controls for C30 and C300,

respectively). At 30 mU/kg per min insulin infusions, the GIR in C300

rats was increased 17% over controls. There were no significant

differences in insulin receptor (IR)-beta, IR substrate (IRS)-1, and

phosphatidylinositol (PI) 3-kinase protein content between C300 rats

and controls. However, the skeletal muscle insulin-stimulated IR-beta

and the IRS-1 tyrosine phosphorylation levels in C300 rats were 18 and

33% higher, respectively, added to 41% higher IRS-1/PI 3-kinase

association. These results suggest that the cinnamon extract would

improve insulin action via increasing glucose uptake in vivo, at least

in part through enhancing the insulin-signaling pathway in skeletal

muscle.

PMID: 14625128

===

Diabetes Care. 2003 Dec;26(12):3215-8.

Cinnamon improves glucose and lipids of people with type 2 diabetes.

Khan A, Safdar M, Ali Khan MM, Khattak KN, RA.

Department of Human Nutrition, NWFP Agricultural University,

Peshawar, Pakistan.

OBJECTIVE: The objective of this study was to determine whether

cinnamon improves blood glucose, triglyceride, total cholesterol, HDL

cholesterol, and LDL cholesterol levels in people with type 2

diabetes. RESEARCH DESIGN AND METHODS: A total of 60 people with type

2 diabetes, 30 men and 30 women aged 52.2 +/- 6.32 years, were divided

randomly into six groups. Groups 1, 2, and 3 consumed 1, 3, or 6 g of

cinnamon daily, respectively, and groups 4, 5, and 6 were given

placebo capsules corresponding to the number of capsules consumed for

the three levels of cinnamon. The cinnamon was consumed for 40 days

followed by a 20-day washout period. RESULTS: After 40 days, all three

levels of cinnamon reduced the mean fasting serum glucose (18-29%),

triglyceride (23-30%), LDL cholesterol (7-27%), and total cholesterol

(12-26%) levels; no significant changes were noted in the placebo

groups. Changes in HDL cholesterol were not significant. CONCLUSIONS:

The results of this study demonstrate that intake of 1, 3, or 6 g of

cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol,

and total cholesterol in people with type 2 diabetes and suggest that

the inclusion of cinnamon in the diet of people with type 2 diabetes

will reduce risk factors associated with diabetes and cardiovascular

diseases.

PMID: 14633804

[Guest guest]

--- In , " rizwankherati " <helper11@e...>

wrote:

> Hi,

>

> I am a non diabetic man with some insulin resistance and FBS leves of

> 100+, I was considering the use of Metformin for its potential life

> extension benefits. However, the following study appears to be

> troubling. I request comments and opinions and any other relevent

studies/facts.

>

> Best regards

>

> Rizwan Kherati

>

Rizwan,

Metformin may cause lactic acidosis which can be fatal. The sudden

development of a slow or irregular heartbeat may be a sign of lactic

acidosis.

http://www.drugs.com/metformin.html

Check with your doctor, but before taking any drugs, you may want to

try cutting down your calories, specially carbohydrates, and adding a

teaspoon of cinnamon to your daily diet. Check out the following sources.

Tony

================

How I Defeated Type II Diabetes

http://shurie.com/lee/writing_defeat_diabetes.htm

===

Diabetes Res Clin Pract. 2003 Dec;62(3):139-48.

Cinnamon extract (traditional herb) potentiates in vivo

insulin-regulated glucose utilization via enhancing insulin signaling

in rats.

Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y.

Department of Sports Medicine, Graduate School of Medicine, Nagoya

University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan.

Cinnamon has been shown to potentiate the insulin effect through

upregulation of the glucose uptake in cultured adipocytes. In the

present study, we evaluated the effect of the cinnamon extract on the

insulin action in awaked rats by the euglycemic clamp and further

analyzed possible changes in insulin signaling occurred in skeletal

muscle. The rats were divided into saline and cinnamon extract (30 and

300 mg/kg BW-doses: C30 and C300) oral administration groups. After

3-weeks, cinnamon extract treated rats showed a significantly higher

glucose infusion rate (GIR) at 3 mU/kg per min insulin infusions

compared with controls (118 and 146% of controls for C30 and C300,

respectively). At 30 mU/kg per min insulin infusions, the GIR in C300

rats was increased 17% over controls. There were no significant

differences in insulin receptor (IR)-beta, IR substrate (IRS)-1, and

phosphatidylinositol (PI) 3-kinase protein content between C300 rats

and controls. However, the skeletal muscle insulin-stimulated IR-beta

and the IRS-1 tyrosine phosphorylation levels in C300 rats were 18 and

33% higher, respectively, added to 41% higher IRS-1/PI 3-kinase

association. These results suggest that the cinnamon extract would

improve insulin action via increasing glucose uptake in vivo, at least

in part through enhancing the insulin-signaling pathway in skeletal

muscle.

PMID: 14625128

===

Diabetes Care. 2003 Dec;26(12):3215-8.

Cinnamon improves glucose and lipids of people with type 2 diabetes.

Khan A, Safdar M, Ali Khan MM, Khattak KN, RA.

Department of Human Nutrition, NWFP Agricultural University,

Peshawar, Pakistan.

OBJECTIVE: The objective of this study was to determine whether

cinnamon improves blood glucose, triglyceride, total cholesterol, HDL

cholesterol, and LDL cholesterol levels in people with type 2

diabetes. RESEARCH DESIGN AND METHODS: A total of 60 people with type

2 diabetes, 30 men and 30 women aged 52.2 +/- 6.32 years, were divided

randomly into six groups. Groups 1, 2, and 3 consumed 1, 3, or 6 g of

cinnamon daily, respectively, and groups 4, 5, and 6 were given

placebo capsules corresponding to the number of capsules consumed for

the three levels of cinnamon. The cinnamon was consumed for 40 days

followed by a 20-day washout period. RESULTS: After 40 days, all three

levels of cinnamon reduced the mean fasting serum glucose (18-29%),

triglyceride (23-30%), LDL cholesterol (7-27%), and total cholesterol

(12-26%) levels; no significant changes were noted in the placebo

groups. Changes in HDL cholesterol were not significant. CONCLUSIONS:

The results of this study demonstrate that intake of 1, 3, or 6 g of

cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol,

and total cholesterol in people with type 2 diabetes and suggest that

the inclusion of cinnamon in the diet of people with type 2 diabetes

will reduce risk factors associated with diabetes and cardiovascular

diseases.

PMID: 14633804

[Guest guest]

Hi All,

As an introduction, see the full-text-free-to-all paper:

Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J.

Improvement in glucose tolerance and insulin resistance in obese subjects

treated

with troglitazone.

N Engl J Med. 1994 Nov 3;331(18):1188-93.

PMID: 7935656

http://content.nejm.org.qe2a-proxy.mun.ca/cgi/content/full/331/18/1188?ijkey=497\

ae3eecbc5cd99c09bb5f17f5af8aadb717b8e

Here is the paper whose message concerned you, the pdf of which is available.

Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H.

Long term cardiovascular effects of oral antidiabetic agents in non-diabetic

patients with insulin resistance: double blind, prospective, randomised study.

Heart. 2005 May;91(5):589-94.

PMID: 15831640

ABSTRACT

Objective: To study the long term cardiovascular effects of oral antidiabetic

agents

in non-diabetic patients with insulin resistance.

Patients: 181 African American subjects with insulin resistance and normal

glucose

tolerance test were randomised to receive glipizide 5 mg/day (n = 25), metformin

500

mg/day (n = 59), or placebo (n = 97) for 24 months. Insulin sensitivity, glucose

tolerance, lipid profile, left ventricular mass (echocardiography), aortic

distensibility (echocardiography, blood pressure), aortic pulse wave velocity

(PWV,

carotid to femoral artery, Doppler) were measured at baseline and at 12 and 24

months after randomisation.

Results: A significant increase in PWV was observed in both glipizide (mean

(SEM)

change at 24 months 2.8 (2.7) m/s, p = 0.012) and metformin (2.2 (0.7) m/s, p =

0.01) groups during the follow up period. In contrast, PWV remained unchanged in

the

placebo group. The increase in PWV in the treatment groups was significant

compared

with placebo (analysis of variance p < 0.05). Other cardiovascular or metabolic

variables did not change significantly compared with placebo during follow up.

Conclusions: The observed increase in PWV is consistent with a decrease in the

elastic properties of the aorta. The use of oral antidiabetic agents for the

prevention of cardiovascular complications in non-diabetic African Americans

with

insulin resistance needs to be critically evaluated.

--- rizwankherati <helper11@...> wrote:

> Hi,

>

> I am a non diabetic man with some insulin resistance and FBS leves of

> 100+, I was considering the use of Metformin for its potential life

> extension benefits. However, the following study appears to be

> troubling. I request comments and opinions and any other relevent

studies/facts.

> Heart 2005;91:589-594.

Al Pater, PhD; email: old542000@...

__________________________________

- PC Magazine Editors' Choice 2005

http://mail.

[Guest guest]

Hi All,

As an introduction, see the full-text-free-to-all paper:

Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J.

Improvement in glucose tolerance and insulin resistance in obese subjects

treated

with troglitazone.

N Engl J Med. 1994 Nov 3;331(18):1188-93.

PMID: 7935656

http://content.nejm.org.qe2a-proxy.mun.ca/cgi/content/full/331/18/1188?ijkey=497\

ae3eecbc5cd99c09bb5f17f5af8aadb717b8e

Here is the paper whose message concerned you, the pdf of which is available.

Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H.

Long term cardiovascular effects of oral antidiabetic agents in non-diabetic

patients with insulin resistance: double blind, prospective, randomised study.

Heart. 2005 May;91(5):589-94.

PMID: 15831640

ABSTRACT

Objective: To study the long term cardiovascular effects of oral antidiabetic

agents

in non-diabetic patients with insulin resistance.

Patients: 181 African American subjects with insulin resistance and normal

glucose

tolerance test were randomised to receive glipizide 5 mg/day (n = 25), metformin

500

mg/day (n = 59), or placebo (n = 97) for 24 months. Insulin sensitivity, glucose

tolerance, lipid profile, left ventricular mass (echocardiography), aortic

distensibility (echocardiography, blood pressure), aortic pulse wave velocity

(PWV,

carotid to femoral artery, Doppler) were measured at baseline and at 12 and 24

months after randomisation.

Results: A significant increase in PWV was observed in both glipizide (mean

(SEM)

change at 24 months 2.8 (2.7) m/s, p = 0.012) and metformin (2.2 (0.7) m/s, p =

0.01) groups during the follow up period. In contrast, PWV remained unchanged in

the

placebo group. The increase in PWV in the treatment groups was significant

compared

with placebo (analysis of variance p < 0.05). Other cardiovascular or metabolic

variables did not change significantly compared with placebo during follow up.

Conclusions: The observed increase in PWV is consistent with a decrease in the

elastic properties of the aorta. The use of oral antidiabetic agents for the

prevention of cardiovascular complications in non-diabetic African Americans

with

insulin resistance needs to be critically evaluated.

--- rizwankherati <helper11@...> wrote:

> Hi,

>

> I am a non diabetic man with some insulin resistance and FBS leves of

> 100+, I was considering the use of Metformin for its potential life

> extension benefits. However, the following study appears to be

> troubling. I request comments and opinions and any other relevent

studies/facts.

> Heart 2005;91:589-594.

Al Pater, PhD; email: old542000@...

__________________________________

- PC Magazine Editors' Choice 2005

http://mail.